NCT01605318 - Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 12, 2013

Primary Completion Date

January 3, 2017

Study Completion Date

January 3, 2017

Conditions

Metastatic Colorectal CancerColon CancerRectal Cancer

Interventions

DRUG

Labetuzumab Govitecan (LG)

Administered as a slow intravenous (IV) infusion.

Trial Locations (7)

Fox Chase, Philadelphia

Helen F. Graham Cancer Center-Christiana Care, Newark

Vanderbilt-Ingram Cancer Center, Nashville

The Ohio State University Comprehensive Cancer Center, Columbus

IUHealth Goshen Center for Cancer Care, Goshen

University of Colorado Anschutz Medical Campus, Aurora

UCLA Jonsson Comprehensive Cancer Center, Santa Monica